戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 d an angiotensin II type 1 receptor blocker (olmesartan).
2 locker methyllycaconitine, (3) sham, and (4) olmesartan.
3 did not match the known pose and affinity of Olmesartan.
4 .5 mm Hg (95% CI, -8.2 to -0.8; P = .02) for olmesartan.
5  with indapamide 2.5 mg, amlodipine 5 mg, or olmesartan 40 mg (4:7:10 randomization), each administer
6 ther an Ang II type 1 receptor blocker (ARB; olmesartan, 5 mg/d) or a triple therapy (hydralazine 7.5
7 to angiotensin II receptor blockers, such as olmesartan, along with travel histories to identify pote
8                                              Olmesartan also increased ace2 expression in the intesti
9                                         Both olmesartan and captopril significantly increased ace2 ex
10 ebrafish with the RAAS inhibitors aliskiren, olmesartan, and captopril for 7 consecutive days and per
11                                              Olmesartan attenuated urinary albumin excretion in adeni
12 uman AT1R in complex with an inverse agonist olmesartan (Benicar(TM)), a highly potent anti-hypertens
13                     The crystal structure of olmesartan-bound human AT1R (PDB:4ZUD) served as a templ
14 s between AT1R and different ARBs, including olmesartan derivatives with inverse agonist, neutral ant
15 caconitine attenuated these effects, whereas olmesartan did not improve cardiac function or fibrosis
16                                 In addition, olmesartan exhibited the ability to reduce phosphorylati
17 uring follow-up (placebo group, 44 888 ECGs; olmesartan group, 42 930 ECGs).
18 ompassed 425 patients (placebo group, n=211; olmesartan group, n=214).
19                                              Olmesartan is anchored to the receptor primarily by the
20 ning FDA approval: azilsartan medoxomil (6), olmesartan medoxomil (20), and ceftobiprole medocaril (2
21 PAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden
22 : losartan potassium, irbesartan, valsartan, olmesartan medoxomil, and telmisartan.
23 rovided more accurate poses and affinity for Olmesartan (n = 6).
24  disease were randomized to placebo or 40 mg olmesartan per day.
25 enazepril 5.0 (r(2) = 0.9291, p < 0.0001) or Olmesartan (r(2) = 0.90, p = 0.0001).
26                                    Of these, olmesartan significantly elevated the expression of sarc
27              In contrast, both captopril and olmesartan significantly improved cardiac function and r
28 te treatment with indapamide, amlodipine, or olmesartan, the addition of single-dose zilebesiran resu
29 e to renin-angiotensin system (RAS) blocker (olmesartan) treatment in these mice.
30 e stable AT1R was used as a template to dock Olmesartan via AutoDock 4.2, MOE, and AutoDock Vina to o
31  240 receiving amlodipine, and 293 receiving olmesartan) were randomized to receive zilebesiran (n =